Skip to content
Saturday 22 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,816.56
+0.64%
DAX
26,136.56
+0.59%
CAC 40
8,484.43
+0.37%
STOXX 50
6,462.22
+0.63%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 15 March 2021 8:07 pm  |  Updated:  Monday 15 March 2021 8:08 pm

US may approve Astrazeneca vaccine in April, even as EU states ban jab over blood clot fears

By: Reuters

Add as a preferred source on Google
ASTRAZENECA-COVID19-VACCINE-APPROVAL
A vial of Astrazeneca Covid-19 vaccine in Saxony during the coronavirus pandemic (Photo by Jens Schlueter/Getty Images)

Results of Astrazeneca’s Covid-19 vaccine trial are being reviewed by independent monitors, and emergency authorisation could come in about a month, a top US official told Reuters today.

The independent monitors are analysing data from the 32,000-person US study to determine whether the vaccine is safe and effective. If the results are positive and all goes well, the US Food and Drug Administration would review the data and issue the authorization, Dr. Francis Collins, director of the National Institutes of Health (NIH), said in an interview.

Collins estimates that the FDA would need about three weeks to analyse the trial data, after which an expert advisory panel will meet and vote on whether to recommend authorisation.

“We expect data from our US Phase Three trial to be available soon, and we plan to file for emergency use authorization shortly thereafter,” Astrazeneca spokeswoman Michele Meixell said in a statement.

Independent monitoring boards periodically review data during clinical trials to make sure no safety problems crop up, and can halt studies early if it determines a drug or vaccine is likely to fail or is clearly going to be a success.

The Astrazeneca vaccine, developed with the University of Oxford, has been authorized for use in the European Union and many countries based on separate trial data. USregulators have been waiting for the US data.

Several EU countries have halted administering the AstraZeneca vaccine after reports from Denmark and Norway of possible serious side effects, including bleeding and blood clots.

Asked about those issues, Collins said he has not personally seen the data but has been “pretty reassured” by statements from European regulators that the problems could be occurring by chance, and are not related to the vaccine.

With so many people being vaccinated, Collins said, some are bound to experience a blood clot around the same time they receive a vaccine.

A World Health Organization expert said today he sees no association between reports of blood clots and the AstraZeneca vaccine and urged people not to panic.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • AstraZeneca
  • Company
  • Coronavirus
  • Vaccine

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • Ratcliffe’s Ineos saves Runcorn plant

  • Amazon says it buys books in bulk to ‘improve products’

  • Mike Ashley’s Frasers offers to pay personal shoppers in Harvey Nichols takeover

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • Perpetuals Reports 380% Hypothetical Return in Backtest of AI Engine Powering Risk-Free Trading Platform ‘UpsideOnly’

    Business Wire
  • ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

    Business Wire
  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

    FTSE 100 Live
    Donald Trump speaking at a podium, microphone visible, discussing the Strait of Hormuz
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook